• Users Online: 200
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2022  |  Volume : 34  |  Issue : 3  |  Page : 240-244

Efficacy, feasibility, and patient acceptance of using low-dose atropine in retarding myopia progression: A general ophthalmologist's perspective

1 Departments of Ophthalmology, Malabar Medical College Hospital and Research Centre, Kozhikode, Kerala, India
2 Department of Ophthalmology, Kannur Medical College, Kannur, Kerala, India
3 ENT, Malabar Medical College Hospital and Research Centre, Kozhikode, Kerala, India
4 Department of Ophthalmology, Al Salama Eye Hospital, Kozhikode, Kerala, India
5 Department of Community Medicine, SIMS and RC, Bengaluru, Karnataka, India

Correspondence Address:
Dr. Lakshmi Cherungottil
Department of Ophthalmology, Malabar Medical College Hospital and Research Center, Kozhikode, Kerala
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/kjo.kjo_99_21

Rights and Permissions

Purpose: Assessing efficacy of atropine 0.01% eye drops in retarding myopia progression in children, the feasibility of its use, and patient acceptance outside institutional practice. Design: Prospective observational hospital-based study was conducted in children who were prescribed aropine 0.01% eye drops to retard the progression of myopia. Methods: Fifty-seven children who showed a documented progression of ≥0.5 diopters (D) of myopia were prescribed atropine 0.01% eyedrops. In those patients who followed up, the mean change in spherical equivalent was assessed using a paired t-test and a pairwise correlation test. Data of those who were lost to follow-up were evaluated. Results: Out of the 57 children 10 opted out of the study and of the remaining 47 children 20 (42.55%) were lost to follow-up. The mean age of the remaining 27 children was 9.04 ± 3.05 years and 48.1% (n = 13) were female. The mean age of dropouts was significantly higher than those who were followed up (P = 0.003). The mean duration of follow-up was 10.8 ± 5.1 months (range 3–23 months). The mean spherical equivalent from baseline to last follow-up was 0.329 by the paired sample t-test (P < 0.001). Twelve (44.4%) of the 27 children showed a progression of myopia despite treatment. Conclusion: Mean change in spherical equivalent in our study is comparable to previous studies with hardly any adverse effects suggesting efficacy of atropine 0.01%; practical hurdles in follow-up and adherence need to be improved with better patient education.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded25    
    Comments [Add]    

Recommend this journal